Biogen · Multi-Quarter Financial Trends

16 quarters · As reported by the company · Amounts in USD billions← BIIB

Quarter	Period End	Revenue ($B)	YoY	Gross Margin	Operating Income ($B)	Net Income ($B)	Net Margin	Free Cash Flow ($B)	EPS	Buybacks ($B)	Dividends ($B)
FY2026 Q3	2026-09-30	2.80	+10.6%	73.3%	—	-0.02	-0.7%	0.60	-0.14	—	—
FY2026 Q2	2026-06-30	2.74	+3.4%	71.6%	—	0.10	3.6%	0.41	0.66	—	—
FY2026 Q1	2026-03-31	2.48	+1.9%	73.3%	—	0.32	12.9%	0.59	2.15	—	—
FY2025 Q4	2025-12-31	2.28	−7.1%	78.3%	—	-0.05	-2.1%	0.47	-0.35	—	—
FY2025 Q3	2025-09-30	2.53	+2.8%	73.4%	—	0.47	18.4%	1.23	3.17	—	—
FY2025 Q2	2025-06-30	2.65	+7.3%	77.1%	—	0.63	24.0%	0.13	4.33	—	—
FY2025 Q1	2025-03-31	2.43	+6.1%	74.1%	—	0.24	9.9%	0.22	1.64	—	—
FY2024 Q4	2024-12-31	2.45	+2.9%	76.2%	—	0.27	10.9%	0.72	1.82	—	—
FY2024 Q3	2024-09-30	2.47	−2.5%	74.1%	—	0.39	15.8%	0.90	2.66	—	—
FY2024 Q2	2024-06-30	2.46	+0.4%	77.8%	—	0.58	23.7%	0.59	4.00	—	—
FY2024 Q1	2024-03-31	2.29	−7.0%	76.3%	—	0.39	17.2%	0.51	2.70	—	—
FY2023 Q4	2023-12-31	2.39	−6.2%	74.1%	—	0.25	10.5%	-0.05	1.70	0.00	—
FY2023 Q3	2023-09-30	2.53	—	73.9%	—	-0.07	-2.7%	0.52	-0.47	0.00	—
FY2023 Q2	2023-06-30	2.46	—	75.9%	—	0.59	24.1%	0.42	4.07	—	—
FY2023 Q1	2023-03-31	2.46	—	73.1%	—	0.39	15.7%	0.39	2.67	—	—
FY2022 Q4	2022-12-31	2.54	—	77.6%	—	0.55	21.6%	-0.26	3.73	0.00	—

Quarterly figures come from the company's 10-Q and 10-K filings. The fourth quarter is derived as the full year minus the first three quarters; cash flow items are converted from fiscal year-to-date totals into single quarters.